Author

Mamta Kalra

Observed names: M. Kalra, MAMTA KALRA

Observed institutions: Oklahoma State University, Houston Methodist, Baylor College of Medicine, Northeastern State University, Johannes Gutenberg University Mainz, University Medical Center Hamburg-Eppendorf, Texas Children's Hospital, Oklahoma State University at Tulsa, Laureate Institute for Brain Research, University of Oklahoma - Tulsa, Post Graduate Institute of Medical Education and Research, Oklahoma State University Center for Health Sciences, Colorado State University

OpenAlex ID: A5022938948

HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma

2017 · Nabil Ahmed, Vita Brawley, et al. · JAMA Oncology · 884

Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma

2020 · Meenakshi Hegde, Sujith K. Joseph, et al. · Nature Communications · 175

PDF

Role of sex steroid receptors in pathobiology of hepatocellular carcinoma

2008 · Mamta Kalra, Jary Mayes, et al. · World Journal of Gastroenterology · 142

PDF

Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial

2024 · Meenakshi Hegde, Shoba Navai, et al. · Nature Cancer · 114

PDF

Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

2025 · Martin Wermke, Dejka M. Araujo, et al. · Nature Medicine · 78

Estrogen receptor expression in chronic hepatitis C and hepatocellular carcinoma pathogenesis

2017 · Janaki K Iyer, Mamta Kalra, et al. · World Journal of Gastroenterology · 69

PDF

Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.

2015 · Nabil Ahmed, Vita Brawley, et al. · Journal for ImmunoTherapy of Cancer · 61

PDF

Status of bacterial colonization, Toll-like receptor expression and nuclear factor-kappa B activation in normal and diseased human livers

2010 · Rashmi Singh, Jay Bullard, et al. · Clinical Immunology · 48

Tuberculosis subunit vaccine design: The conflict of antigenicity and immunogenicity

2007 · Suraj B. Sable, Mamta Kalra, et al. · Clinical Immunology · 45

Peripheral Blood and Pleural Fluid Mononuclear Cell Responses to Low-Molecular-Mass Secretory Polypeptides ofMycobacterium tuberculosisin Human Models of Immunity to Tuberculosis

2005 · Suraj B. Sable, Rajnish Kumar, et al. · Infection and Immunity · 42

Development of an ultrasensitive polymerase chain reaction–amplified immunoassay based on mycobacterial RD antigens: implications for the serodiagnosis of tuberculosis

2012 · Promod K. Mehta, Mamta Kalra, et al. · Diagnostic Microbiology and Infectious Disease · 36

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors

2024 · Martin Wermke, Tobias A W Holderried, et al. · Journal for ImmunoTherapy of Cancer · 35

Utility of a combination of RD1 and RD2 antigens as a diagnostic marker for tuberculosis

2009 · Mamta Kalra, Gopal Krishan Khuller, et al. · Diagnostic Microbiology and Infectious Disease · 32

Supplementation with RD antigens enhances the protective efficacy of BCG in tuberculous mice

2007 · Mamta Kalra, Ajay Grover, et al. · Clinical Immunology · 30

Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy

2018 · MAMTA KALRA, ULRIKE GERDEMANN, et al. · Cytotherapy · 22

959 Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial

2021 · Martin Wermke, Apostolia-Maria Tsimberidou, et al. · Journal for ImmunoTherapy of Cancer · 18

PDF

Abstract PR018: IMA203 TCR-T targeting PRAME demonstrates potent anti-tumor activity in patients with different types of metastatic solid tumors

2023 · Martin Wermke, Winfried Alsdorf, et al. · Molecular Cancer Therapeutics · 17

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

2016 · Andreas Lundqvist, Vincent van Hoef, et al. · Journal for ImmunoTherapy of Cancer · 11

PDF

Evaluation of Mycobacterium tuberculosis specific RD antigens for delayed type hypersensitivity responses in guinea pig.

2010 · Mamta Kalra, Gopal Krishen Khuller, et al. · PubMed · 11

Author Correction: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

2025 · Martin Wermke, Dejka M. Araujo, et al. · Nature Medicine · 7

PDF

Proceedings of the 7th Biannual International Symposium on Nasopharyngeal Carcinoma 2015

2016 · IB Tan, Ellen T. Chang, et al. · BMC Proceedings · 4

PDF

163 Improved anti-tumor activity of next-generation TCR-engineered T cells through CD8 co-expression

2021 · Gagan Bajwa, Justin Gunesch, et al. · Journal for ImmunoTherapy of Cancer · 3

PDF

293 Resultsof the first-in-human clinical trial with personalized multi-target adoptive cell therapy (ACTolog IMA101)

2020 · Apostolia Tsimberidou, Kerstin Guenther, et al. · Journal for ImmunoTherapy of Cancer · 2

OR.72. Impact of Bacterial Colonization in Normal Human Livers on Activation of Toll-like Receptor 4 and Nuclear Factor kappa B and Their Possible Role in Maintaining Homeostasis

2008 · Rashmi Singh, Jay Bullard, et al. · Clinical Immunology · 2

226 An effective donor screening program for manufacturing of allogeneic γδ T cell products

2024 · Inbar Alfaguter, Christopher Lanier, et al. · Journal for ImmunoTherapy of Cancer · 1

Works count: 36

Citation count: 1,893

H-index: 17

I10-index: 19